Eplerenone displays antihypertensive, anti-inflammatory, and anti-angiogenic activities; it inhibits the mineralocorticoid receptor. Eplerenone inhibits aldosterone-induced expression of COX (therefore decreasing PGE2 levels), preventing the induction of COX and resulting kidney damage in high salt diets. This compound also prevents salt-induced increases in NOX expression, decreasing oxidative stress in the kidney as well. In spontaneously hypertensive rats, eplerenone inhibited cardiac remodeling (hypertrophy) and left ventricle dysfunction. The antiangiogenic activity of eplerenone is characterized by its inhibition of VEGF expression in the kidney.